Showing results (231-240 of 280) with videos related to

Sort By:
Pageof 28
Journal of the National Comprehensive Cancer Network : JNCCN|September 2, 2020
Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 PandemicElizabeth A Griffiths, Laura M Alwan, Kimo Bachiashvili, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 25, 2024
Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes-Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS])Fnu Aakash, Savanah D Gisriel, Amer M Zeidan, et al.
The Journal of Clinical Investigation|December 7, 2023
PD-1H/VISTA mediates immune evasion in acute myeloid leukemiaTae Kon Kim, Xue Han, Qianni Hu, et al.
The Journal of Biological Chemistry|May 3, 2011
Aberrant epigenetic and genetic marks are seen in myelodysplastic leukocytes and reveal Dock4 as a candidate pathogenic gene on chromosome 7qLi Zhou, Joanna Opalinska, Davendra Sohal, et al.
Blood Advances|February 11, 2026
A novel approach to defining progression in MDS and precursor myeloid conditions in The MDS Natural History StudyAmy E DeZern, Nancy Gillis, Michael Otterstatter, et al.
Cancer|March 13, 2026
A phase 1 study of berzosertib (M6620, VX-970) in combination with cisplatin and radiation in patients with locally advanced head and neck squamous cell carcinoma (ETCTN 9950)Aarti Bhatia, Zhengjia Chen, Yuji Zhang, et al.
Leukemia & Lymphoma|May 22, 2019
The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromesMikkael A Sekeres, Steven D Gore, Donald M Stablein, et al.
Blood Cancer Journal|March 31, 2025
Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched studyAlex Bataller, Koji Sasaki, Samuel Urrutia, et al.
The Lancet. Oncology|August 29, 2017
Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trialHagop M Kantarjian, Gail J Roboz, Patricia L Kropf, et al.
Blood Advances|April 25, 2018
Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohortMaximilian Stahl, Michelle DeVeaux, Pau Montesinos, et al.
Pageof 28